ClinicalTrials.gg
RecruitingNCT07274397EARLYBRAINPETUpdated Jun 8, 2026

Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma

An interventional study of Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium in Glioblastoma, Brain Tumors and Brain Imaging, sponsored by Beta Emitting Accurate Monitored Systems. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Beta Emitting Accurate Monitored Systems · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 150 studies in Glioblastoma with a site in France — 35 open to participants now, 51 under way, 9 of them phase 3. Glioblastoma · France.

Planned enrollment
123rd of 131
15 · median 80
Started
2026
with 7 others
No phase
28 of 150
14 open now
Primary completion
2027-04
later than 21 of 50 live
Registered
144th of 150
by date

Among the 150 studies in Glioblastoma with a site in France, this one is the 123rd largest by planned enrollment of the 131 interventional ones that give a count, is one of 8 that started in 2026, is one of 28 with no phase, reaches primary completion later than 21 of the 50 other live ones, and was the 144th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

35 of the 150 studies in Glioblastoma with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Glioblastoma with a site in France, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma. The study also seeks to validate specific nuclear imaging parameters for better detection of residual tumor tissue compared to standard gadolinium-enhanced MRI. The main objectives are to determine whether early PET-MRI within 48 hours post-surgery is feasible, to assess potential side effects related to imaging procedures, and to explore if PET parameters such as SUVmax, metabolic volume, and tumor-to-striatum ratio can improve the detection of tumor residue. A total of 15 patients will be included at a single site in France. Participants will undergo PET-MRI using 18F-DOPA and gadolinium, and will be monitored for radiation exposure and possible adverse events up to 24 hours after imaging.

Read the detailed description

This study aims to assess safety and feasibility of early post-operative PET-MRI and validate imaging parameters for detecting glioblastoma residue, enabling future personalized post-surgical care.

The primary objectives are to :

  • Asses the safety of performing early post-operative brain PET-MRI in neurosurgery patients after glioblastoma surgery.
  • Measure the nuclear exposition of patients when performing early post-operative brain PET-MRI in neurosurgery patients.
  • Assess the feasibility of performing early post-operative brain PET-MRI in neurosurgery patients.

It is a prospective interventional diagnostic study involving patient comparison Category RIPH. 15 patients will be included. This is a monocentric study. One surgical and including site (CHU Henri Mondor), in one country (France).

Patients will participate during 24 hours. The duration of the study is 12 months.

Following gadolinium injection, patients will be monitored for at least 30 minutes to allow for the early detection of potential side effects. Immediate hypersensitivity reactions, including anaphylactoid responses or other idiosyncratic effects, may present with cardiovascular, respiratory, or cutaneous symptoms, and can be severe.

Although delayed reactions are rare, most immediate events occur within the first 30 minutes post-administration. Monitoring is routinely implemented in clinical practice and will be applied accordingly in the study.

18F-DOPA injection can induce pain at the injection site, probably due to the acidity of the product. Given the minimal quantity of substance administered, the primary risk is associated with the exposure to ionizing radiation. In theory, such exposure may induce carcinogenesis or result in the development of hereditary defects. Nevertheless, since the effective dose is approximately 7 mSv and we are well below the maximum recommended activity of 280 MBq, the probability of these adverse effects occurring is considered very low.

2. MRI

  1. Diffusion B1500
  2. SWI
  3. 3D FLAIR
  4. 3D T1 SPACE
  5. ASL
  6. Spectroscopy (TE short et TE long) in the tumoral surroundings
  7. After gadolinium injection : Perfusion T2*, Angio-MRI, 3DT1 SPACE

For PET-MRI imaging, tracer administration and acquisition timing will follow standard clinical protocols. For 18F-DOPA, a static brain acquisition will be performed between 10- and 30-minutes post-injection, as recommended for glioma imaging.

Study design is as follow :

  • Pre-surgical baseline evaluation: 30 days - 2 days prior to surgery
  • Patient information
  • Medical History and Treatment, clinical assessment
  • Preoperative Brain MRI and PET-MRI as detailed hereabove.

Patients usually undergo preoperative brain PET-MRI with gadolinium enhancement and 18F-DOPA injection as a standard of care. No specific period of time will be necessary to schedule the surgery after this imaging.

  • D0: Neurosurgical procedure for tumor resection, as decided by the neurosurgeon, under general anesthesia
  • Between D0 post-surgery and D2: patient informed consent and inclusion

    • H0: Patient informed consent and inclusion
    • Baseline medical examination
    • Patient transferred to the nuclear medicine department
    • Positioning of a dosimeter
    • Radiotracer intravenous injection
    • For suspected glioblastoma:

      18F-Dopa 2MBq/kg, starting the imaging immediately after injection

    • Postoperative brain PET-MRI acquisition
    • Surveillance time in nuclear medicine according to standard procedures
    • Patient transferred back to the neurosurgery department
    • Surveillance time: 24 hours dosimetry measurements
    • End of inclusion medical examination
    • Removing the dosimeter
    • H24: End of patient inclusion Neurosurgical follow-up and home discharge as established by the referent per clinical practice.

No medicinal product with therapeutic intent are administered in this study, only imaging agents usually used in clinical practice for diagnostic purposes are employed. The remainder of the patient's care will be managed according to the standard of care.

Only diagnostic imaging agents routinely used in standard clinical neuroimaging protocols will be administered during the study.

Gadolinium-based contrast agents will be used for MRI sequences requiring enhancement.

For PET imaging, 18F-DOPA will be employed. All imaging agents will be used under standard clinical conditions, in accordance with current safety and administration guidelines.

03

Conditions studied

  • Glioblastoma
  • Brain Tumors
  • Brain Imaging

Keywords

  • Glioblastoma
  • brain tumors
  • PET-MRI
  • 18F-DOPA
  • Radiotracer
  • Diagnostic Imaging
  • Nuclear Medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First resection for a suspected glioblastoma in the past 72h
  • Signed

non-inclusion Criteria:

  • Deprived of liberty or under legal protection (e.g, guardianship, trusteeship)
  • Patients under 18 years old
  • Absence of social security cover
  • Pregnancy
  • Emergency procedure
  • to brain MRI, including claustrophobia
  • Contraindication to radiotracers or gadolinium injection
  • Preoperative cognitive impairment impeding patient information

Exclusion criteria

Exclusion criteria :

  • Any postoperative behavioral disorders or medical condition or symptom impeding the completion of brain imaging
  • Postoperative medical dependency impeding the patient transfer to the nuclear medicine department (including, but not limited to, invasive ventilation, need for external ventricular drainage…)
  • Postoperative histological diagnosis different from glioblastoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Other
    Early post-operative PET-MRI group

    Participants in this arm will undergo early post-operative PET-MRI imaging within 48 hours after surgical resection of a suspected glioblastoma. The imaging procedure includes a brain MRI with gadolinium-based contrast and a PET scan using 18F-DOPA as the radiotracer. Patients will be monitored for potential adverse events related to the imaging agents and for radiation exposure. No therapeutic intervention will be administered. The purpose of this diagnostic intervention is to assess feasibility, safety, and imaging performance in detecting residual tumor tissue.

    Diagnostic Test: Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium

Interventions

  • Diagnostic testEarly post-operative brain PET-MRI with 18F-DOPA and Gadolinium

    This intervention consists of a combined brain PET-MRI imaging session performed within 48 hours after surgical resection of a suspected glioblastoma. The PET scan uses 18F-DOPA as the radiotracer, administered intravenously at a dose of 2 MBq/kg, with static brain acquisition starting immediately post-injection. The MRI includes standard sequences and gadolinium-based contrast-enhanced imaging. The goal is to assess the feasibility and safety of this early post-operative imaging procedure, and to validate imaging parameters for the detection of residual tumor. Radiation dosimetry and potential adverse events related to imaging agents will be monitored.

06

What researchers measure

Primary outcomes

  1. Assess the feasibility of performing early post-operative brain PET-MRI in neurosurgery patients

    by recording the rate of patients excluded after inclusion for non-realized imaging or incomplete imaging, at the physician's or the patient's demand.

    Time frame: Within 24 hours after surgery

  2. Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients

    by collecting side effects associated with radiotracer injection and imaging procedure after surgery during the inclusion period

    Time frame: Within 24 hours after surgery

  3. Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients

    by measuring ambient gamma dose rate at several time points (Hour 0, Hour 1, Hour 2, Hour 4 et Hour 24) on different points according to appendix.

    Time frame: Whithin 24 hours after surgery

  4. Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients

    by measuring ambient gamma dose rate at several time points on different points (on the patient, 50 centimeters, 1 meter, 2 meters from the patient) according to appendix.

    Time frame: Whithin 24 hours afin surgery

  5. Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients

    With total dosimetry after 24 hours

    Time frame: Whithin 24 hours afin surgery

Secondary outcomes

  1. Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients

    by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Dynamic analysis including peak time

    Time frame: 24 hours

  2. Evaluate the inter-raters reliability of nuclear imaging protocol (T/S and T/CC) to evaluate the presence or absence of residual tumor on early post-operative brain PET in neurosurgery patients.

    Images will be reviewed by at least two raters : Kappa coefficient, Percentage agreement

    Time frame: 24 hours

  3. Evaluate the inter-raters reliability of nuclear imaging protocol (metabolic volume with different thresholds) to measure residual tumor volume on early post-operative brain PET in neurosurgery patients.

    Intra-class correlation coefficient

    Time frame: 24 hours

  4. Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients

    by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Dynamic analysis including sleigh

    Time frame: 24 hours

  5. Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients

    by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Dynamic analysis including wash-out period

    Time frame: 24 hours

  6. Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients

    by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Standardized Uptake Value maximum

    Time frame: 24 hours

  7. Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients

    by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Tumour/Striatum ratio (T/S)

    Time frame: 24 hours

  8. Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients

    by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: The rate of discordance between MRI result and PET result will be assessed for each modality

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Hôpital Henri Mondor - Université Paris-Est Créteil (UPEC)
    Créteil, 94010, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 151 interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 88. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Dec 10, 2025
StartActual
Apr 17, 2026
Primary completionEst.
Apr 17, 2027
CompletionEst.
Apr 17, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07274397
Lead sponsor
Beta Emitting Accurate Monitored Systems
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Apr 17, 2026
Primary completion
Apr 17, 2027 (estimated)
Completion
Apr 17, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Caroline Apra, MD, PhD
Contact
contact@beams.bio
+330149812240
Nawel Saci, Msc
Contact
nawelsaci@olexclinical.com
+33667405900

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion